

# Leticia Leon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025158/publications.pdf>

Version: 2024-02-01

45  
papers

874  
citations

516215

16  
h-index

500791

28  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1677  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 639-646.	0.5	157
2	Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1393-1399.	0.5	110
3	Systematic review and critical appraisal of transitional care programmes in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 372-379.	1.6	58
4	Development and validation of a multivariate predictive model for rheumatoid arthritis mortality using a machine learning approach. <i>Scientific Reports</i> , 2017, 7, 10189.	1.6	50
5	Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry. <i>Rheumatology</i> , 2020, 59, 2099-2108.	0.9	48
6	Transitional care for rheumatic conditions in Europe: current clinical practice and available resources. <i>Pediatric Rheumatology</i> , 2017, 15, 49.	0.9	39
7	Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 559-69.	0.4	31
8	Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 456-460.	0.6	30
9	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 226-228.	0.2	27
10	Orthopedic Surgery in Rheumatoid Arthritis in the Era of Biologic Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 1850-1855.	1.0	23
11	Prognostic factors for long-term work disability due to musculoskeletal disorders. <i>Rheumatology International</i> , 2012, 32, 3831-3839.	1.5	20
12	Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 506-513.	1.6	20
13	Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2096269.	1.2	20
14	Effectiveness of an early cognitive-behavioral treatment in patients with work disability due to musculoskeletal disorders. <i>Arthritis and Rheumatism</i> , 2009, 61, 996-1003.	6.7	19
15	A bibliometric study of the scientific publications on patient-reported outcomes in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 828-833.	1.6	19
16	Influence of demographic and clinical factors on the mortality rate of a rheumatoid arthritis cohort: A 20-year survival study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 533-538.	1.6	18
17	Contribution of the bone and cartilage/soft tissue components of the joint damage to the level of disability in rheumatoid arthritis patients: a longitudinal study. <i>Clinical Rheumatology</i> , 2019, 38, 691-700.	1.0	16
18	Mortality rate in rheumatoid arthritis-related interstitial lung disease: the role of radiographic patterns. <i>BMC Pulmonary Medicine</i> , 2021, 21, 205.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 29-35.	0.4	15
20	Negative affect in systemic sclerosis. <i>Rheumatology International</i> , 2014, 34, 597-604.	1.5	13
21	Expert recommendations on the psychological needs of patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2018, 38, 2167-2182.	1.5	12
22	Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac008.	0.3	12
23	Health-related quality of life as a main determinant of access to rheumatologic care. <i>Rheumatology International</i> , 2013, 33, 1797-1804.	1.5	11
24	Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. <i>Pediatric Rheumatology</i> , 2021, 19, 162.	0.9	11
25	Incidence of Physical Disability Related to Musculoskeletal Disorders in the Elderly: Results From a Primary Care-Based Registry. <i>Arthritis Care and Research</i> , 2015, 67, 89-93.	1.5	8
26	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. <i>Reumatología Clínica</i> , 2018, 14, 346-359.	0.2	7
27	Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1987800.	1.2	7
28	Influence of patient personality in the treatment of rheumatoid arthritis. <i>Rheumatology International</i> , 2016, 36, 1549-1555.	1.5	6
29	Costes médicos directos y sus predictores en la cohorte "Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España". <i>Reumatología Clínica</i> , 2018, 14, 4-8.	0.2	6
30	Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 121-128.	0.4	6
31	Validation of a Quality of Life Instrument in Spanish Patients With Rheumatic Diseases. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 78-84.	0.5	5
32	Impact of rheumatoid arthritis on sexuality: adaptation and validation of the Qualisex questionnaire for use in Spain. <i>Rheumatology International</i> , 2022, 42, 1819-1829.	1.5	5
33	Factors Associated with Health-Related Quality of Life in Psoriatic Arthritis Patients: A Longitudinal Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1341-1354.	1.1	4
34	Direct medical costs and their predictors in the EMAR-II cohort: "Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain". <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 4-8.	0.2	3
35	Response to: "Correspondence on Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases" by Aydin et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e70-e70.	0.5	3
36	Treatment in rheumatoid arthritis and mortality risk in clinical practice: the role of biologic agents. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1026-1032.	0.4	3

#	ARTICLE	IF	CITATIONS
37	Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 872-879.	0.4	2
38	Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 165-170.	0.4	2
39	Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210902.	1.2	2
40	An early intervention program for subacute physical disability related to musculoskeletal diseases in the elderly: a pilot study. <i>Rheumatology International</i> , 2015, 35, 1183-1191.	1.5	1
41	Response to: "Correspondence on Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases" by Schulze-Koops et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219230.	0.5	1
42	Development of the Anxiety, Depression and Coping (ADAF) screening tool for emotional and coping problems in cancer patients. <i>Psycho-Oncology</i> , 2021, 30, 1894-1901.	1.0	1
43	Comment on: Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry: reply. <i>Rheumatology</i> , 2020, 59, 2181-2182.	0.9	1
44	Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 173.	0.4	1
45	Emotional regulation processes: influence on pain and disability in fibromyalgia patients. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 123, 40-46.	0.4	1